The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications

Ryota Tamura, Toshihide Tanaka, Yasuharu Akasaki, Yuichi Murayama, Kazunari Yoshida, Hikaru Sasaki

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The microvasculature and immune cells are major components of the tumor microenvironment (TME). Hypoxia plays a pivotal role in the TME through hypoxia-inducible factor 1-alpha (HIF-1α) which upregulates vascular endothelial growth factor (VEGF). VEGF, an angiogenesis stimulator, suppresses tumor immunity by inhibiting the maturation of dendritic cells, and induces immunosuppressive cells such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells. HIF-1α directly induces immune checkpoint molecules. VEGF/VEGF receptor (VEGFR)-targeted therapy as a cancer treatment has not only anti-angiogenic effects, but also immune-supportive effects. Anti-angiogenic therapy has the potential to change the immunological "cold tumors" into the "hot tumors". Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME. Therefore, in the last decade, several combination immunotherapies with anti-angiogenic agents have been developed for numerous tumors including GBs. In particular, combination therapy with an immune checkpoint inhibitor and VEGF/VEGFR-targeted therapy has been suggested as a synergic treatment strategy that may show favorable changes in the TME. In this article, we discuss the cross talk among immunosuppressive cells exposed to VEGF in the hypoxic TME of GBs. Current efficient combination strategies using VEGF/VEGFR-targeted therapy are reviewed and proposed as novel cancer treatments.

Original languageEnglish
Number of pages1
JournalMedical oncology (Northwood, London, England)
Volume37
Issue number1
DOIs
Publication statusPublished - 2019 Nov 11

Fingerprint

Tumor Microenvironment
Immunosuppressive Agents
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor
Neoplasms
Hypoxia-Inducible Factor 1
Therapeutics
Angiogenesis Inducing Agents
Regulatory T-Lymphocytes
Cellular Structures
Glioblastoma
Microvessels
Immunotherapy
Dendritic Cells
Immunity
Up-Regulation
Macrophages

Keywords

  • Hypoxia
  • Immune checkpoint molecule
  • Myeloid-derived suppressor cell
  • Regulatory T cell
  • Tumor microenvironment
  • Tumor-associated macrophage
  • VEGF

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment : perspectives for therapeutic implications. / Tamura, Ryota; Tanaka, Toshihide; Akasaki, Yasuharu; Murayama, Yuichi; Yoshida, Kazunari; Sasaki, Hikaru.

In: Medical oncology (Northwood, London, England), Vol. 37, No. 1, 11.11.2019.

Research output: Contribution to journalReview article

@article{08dc814c74f04509926cd841c9389d6d,
title = "The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications",
abstract = "The microvasculature and immune cells are major components of the tumor microenvironment (TME). Hypoxia plays a pivotal role in the TME through hypoxia-inducible factor 1-alpha (HIF-1α) which upregulates vascular endothelial growth factor (VEGF). VEGF, an angiogenesis stimulator, suppresses tumor immunity by inhibiting the maturation of dendritic cells, and induces immunosuppressive cells such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells. HIF-1α directly induces immune checkpoint molecules. VEGF/VEGF receptor (VEGFR)-targeted therapy as a cancer treatment has not only anti-angiogenic effects, but also immune-supportive effects. Anti-angiogenic therapy has the potential to change the immunological {"}cold tumors{"} into the {"}hot tumors{"}. Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME. Therefore, in the last decade, several combination immunotherapies with anti-angiogenic agents have been developed for numerous tumors including GBs. In particular, combination therapy with an immune checkpoint inhibitor and VEGF/VEGFR-targeted therapy has been suggested as a synergic treatment strategy that may show favorable changes in the TME. In this article, we discuss the cross talk among immunosuppressive cells exposed to VEGF in the hypoxic TME of GBs. Current efficient combination strategies using VEGF/VEGFR-targeted therapy are reviewed and proposed as novel cancer treatments.",
keywords = "Hypoxia, Immune checkpoint molecule, Myeloid-derived suppressor cell, Regulatory T cell, Tumor microenvironment, Tumor-associated macrophage, VEGF",
author = "Ryota Tamura and Toshihide Tanaka and Yasuharu Akasaki and Yuichi Murayama and Kazunari Yoshida and Hikaru Sasaki",
year = "2019",
month = "11",
day = "11",
doi = "10.1007/s12032-019-1329-2",
language = "English",
volume = "37",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment

T2 - perspectives for therapeutic implications

AU - Tamura, Ryota

AU - Tanaka, Toshihide

AU - Akasaki, Yasuharu

AU - Murayama, Yuichi

AU - Yoshida, Kazunari

AU - Sasaki, Hikaru

PY - 2019/11/11

Y1 - 2019/11/11

N2 - The microvasculature and immune cells are major components of the tumor microenvironment (TME). Hypoxia plays a pivotal role in the TME through hypoxia-inducible factor 1-alpha (HIF-1α) which upregulates vascular endothelial growth factor (VEGF). VEGF, an angiogenesis stimulator, suppresses tumor immunity by inhibiting the maturation of dendritic cells, and induces immunosuppressive cells such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells. HIF-1α directly induces immune checkpoint molecules. VEGF/VEGF receptor (VEGFR)-targeted therapy as a cancer treatment has not only anti-angiogenic effects, but also immune-supportive effects. Anti-angiogenic therapy has the potential to change the immunological "cold tumors" into the "hot tumors". Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME. Therefore, in the last decade, several combination immunotherapies with anti-angiogenic agents have been developed for numerous tumors including GBs. In particular, combination therapy with an immune checkpoint inhibitor and VEGF/VEGFR-targeted therapy has been suggested as a synergic treatment strategy that may show favorable changes in the TME. In this article, we discuss the cross talk among immunosuppressive cells exposed to VEGF in the hypoxic TME of GBs. Current efficient combination strategies using VEGF/VEGFR-targeted therapy are reviewed and proposed as novel cancer treatments.

AB - The microvasculature and immune cells are major components of the tumor microenvironment (TME). Hypoxia plays a pivotal role in the TME through hypoxia-inducible factor 1-alpha (HIF-1α) which upregulates vascular endothelial growth factor (VEGF). VEGF, an angiogenesis stimulator, suppresses tumor immunity by inhibiting the maturation of dendritic cells, and induces immunosuppressive cells such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells. HIF-1α directly induces immune checkpoint molecules. VEGF/VEGF receptor (VEGFR)-targeted therapy as a cancer treatment has not only anti-angiogenic effects, but also immune-supportive effects. Anti-angiogenic therapy has the potential to change the immunological "cold tumors" into the "hot tumors". Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME. Therefore, in the last decade, several combination immunotherapies with anti-angiogenic agents have been developed for numerous tumors including GBs. In particular, combination therapy with an immune checkpoint inhibitor and VEGF/VEGFR-targeted therapy has been suggested as a synergic treatment strategy that may show favorable changes in the TME. In this article, we discuss the cross talk among immunosuppressive cells exposed to VEGF in the hypoxic TME of GBs. Current efficient combination strategies using VEGF/VEGFR-targeted therapy are reviewed and proposed as novel cancer treatments.

KW - Hypoxia

KW - Immune checkpoint molecule

KW - Myeloid-derived suppressor cell

KW - Regulatory T cell

KW - Tumor microenvironment

KW - Tumor-associated macrophage

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85074814668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074814668&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1329-2

DO - 10.1007/s12032-019-1329-2

M3 - Review article

C2 - 31713115

AN - SCOPUS:85074814668

VL - 37

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

ER -